Stiefel Laboratories, Inc. Announces Appointment of Dr. Marco Taglietti, MD to Newly Created...

CORAL GABLES, Fla. -- Stiefel Laboratories, the world's largest independent pharmaceutical company specialized in Dermatology, has assigned Dr. Marco Taglietti the responsibility of all Research and Development activities in the three Stiefel R&D centers: Oak Hill (New York, USA), Maidenhead

"Dr. Taglietti's new position at Stiefel is part of the long-term strategy of strengthening and expanding the global reach of Stiefel Laboratories which already boasts a network of wholly-owned subsidiaries in more than 30 countries. His wealth of experience in Drug Development, coupled with our current strong R&D infrastructure, will allow us a quantum leap to the next growth level. We welcome him to our team and anticipate a continued expansion of our R&D activities," announced Charles W. Stiefel, CEO, Chairman of the Board and President.

Dr. Taglietti began his pharmaceutical career in Clinical Research at Marion Merrel Dow Research Institute (now part of Aventis) in Gerenzano, Italy. In 1992, he joined Schering-Plough Research Institute, Kenilworth, New Jersey, where he held numerous positions of increasing responsibility, including the position of Vice President for Worldwide Clinical Research in the therapeutic areas of -- Anti-Infectives, Oncology, Neuroscience, Endocrinology and Dermatology. Dr. Taglietti's development team produced breakthrough drugs for primary brain tumors, invasive fungal infections that develop in organ transplants or in cancer, and drugs for community respiratory bacterial infections.

A native of Italy, Dr. Taglietti earned his medical degree from the University of Pavia in Italy, trained at the University hospital and is Board Certified in both Dermatology and Infectious Diseases. He continues to teach special Clinical Trial Science courses at the University of Pavia.

Dr. Taglietti will report directly to Charles W. Stiefel, CEO, and will be headquartered in Stiefel's corporate offices in Coral Gables, Florida.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories is the world's largest independent pharmaceutical company specializing in Dermatology. Its global network is comprised of more than 30 wholly owned subsidiaries, including: manufacturing plants in six countries; R&D facilities on three continents; and products marketed in over 100 countries worldwide.

Stiefel supplements its R&D by aggressively seeking acquisitions of dermatological product lines and companies around the world.